JOURNAL ARTICLE
META-ANALYSIS
Add like
Add dislike
Add to saved papers

A meta-analysis on Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma in China.

OBJECTIVE: To evaluate the curative effect of Rituximab combined CHOP chemotherapy in patients with non-Hodgkin lymphoma in China.

METHODS: We conducted this study in the Affiliated Shengjing Hospital of China Medical University, Shenyang, China between June and December 2010. We used the systematic review method of The Cochrane Collaboration to collect randomized controlled trials (RCTs) of Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma by computer databases during the period 2004-2009.

RESULTS: Seven trials involving 357 patients were retrieved. The complete remission rate of Rituximab combined CHOP chemotherapy was higher than that of CHOP chemotherapy alone (odds ratio = 3.02, 95% confidence interval: 1.94-4.72, p<0.00001).

CONCLUSION: Non-Hodgkin lymphoma treated by Rituximab combined CHOP chemotherapy can produce a positive therapeutic effect in China.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app